Germany

BMI View: Bayer's diversified portfolio is not heavily dependent on blockbuster drugs and it has limited exposure to the patent cliff. Of all the multinational drugmakers, it generates... 2011-08-01

BMI View: In line with the industry trend for multinational pharmaceutical companies, Boehringer Ingelheim had a difficult year in 2010. The reduction in the company's net profit in... 2011-04-07

BMI View: Merck KGaA has published strong 2010 financial results, but the year will be primarily remembered for cladribine's failure to gain approval and the acquisition of Millipore,... 2011-02-22

BMI View: Mergers and acquisitions (M&A), rather than greenfield investments, will become more popular as a strategy for entry to the pharmaceutical industries of emerging markets.... 2011-01-11

BMI Core View: Pharmaceutical sales forces will contract in developed states and expand in emerging markets. The primary cause of this trend is the declining influence of US and Western... 2010-12-16

BMI View: Despite some disappointing verdicts from regulators on promising drug prospects, Merck Serono's long-term strategy - investing in research, embracing personalised medicine,... 2010-12-14

Pfizer has withdrawn its bid for German pharmaceutical company Ratiopharm , leaving Israel's Teva and Iceland's Actavis to compete for the firm. Teva's position as the... 2010-02-03

Israel's Teva Pharmaceutical Industries has moved to end speculation that it is eying up an acquisition of Germany's Stada Arzneimittel. Teva's North American CEO William Marth stated... 2008-09-22

Highlighting the legal minefield of bioprospecting, Germany's Schwabe Pharmaceuticals is facing a challenge to two European Patent Office (EPO) patents for its phytopharmaceutical... 2008-05-14

The race for the generics business of Germany's Merck KGaA looks to be heading into the final stages with two firms thought to be leading the bidding - Israel's Teva , and US-based... 2007-05-11